Group 1: Company Overview - Peking University Medicine Co., Ltd. was established in 1997 and is listed on the Shenzhen Stock Exchange [2] - The company operates in two main sectors: pharmaceutical manufacturing and pharmaceutical commerce, with a focus on chemical preparations [2][3] - It has wholly-owned subsidiaries in Beijing and Wuhan, primarily engaged in drug distribution, retail, and hospital procurement [2] Group 2: Financial Performance - In 2023, the company achieved a revenue of CNY 2.194 billion, representing a year-on-year growth of 5.61% [3] - The total profit for the year was CNY 74.29 million, an increase of 5.24% compared to the previous year [3] - Net profit attributable to the parent company was CNY 44.36 million, showing a decline of 20.23% year-on-year [3] Group 3: Marketing and Operational Strategies - The company has seen a gradual decrease in marketing expenses due to some products winning national procurement bids [3] - The marketing team is expected to remain stable, with potential stock incentive plans to retain key talents [3] - Accounts receivable are primarily concentrated in the pharmaceutical distribution sector, with manageable risks associated with related parties [3]
北大医药(000788) - 2024年5月29日投资者关系活动记录表